Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept
BackgroundNeovascular age-related macular degeneration (nAMD) is a leading cause of blindness in older people. Low-grade inflammation is well-known as one of the pathogenic mechanisms in nAMD. Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for nAMD, although macul...
Main Authors: | Tomohito Sato, Toshio Enoki, Yoko Karasawa, Hideaki Someya, Manzo Taguchi, Kozo Harimoto, Kei Takayama, Takayuki Kanda, Masataka Ito, Masaru Takeuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.738521/full |
Similar Items
-
Elevated Levels of Serum IL-17A Secondary to Repeated Intravitreal Injections of Aflibercept in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration
by: Małgorzata Seredyka-Burduk, et al.
Published: (2020-06-01) -
Association between Systemic Factors and Vitreous Fluid Cytokines in Proliferative Diabetic Retinopathy
by: Tomohito Sato, et al.
Published: (2023-03-01) -
Progress of Aflibercept of clinical application for neovascular age-related macular degeneration
by: Yun-Yan Zheng, et al.
Published: (2021-10-01) -
Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01) -
Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01)